25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Propanc Biopharma Inc
Buy, Hold or Sell?

Let's analyze Propanc together

I guess you are interested in Propanc Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Propanc Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Propanc Biopharma Inc

I send you an email if I find something interesting about Propanc Biopharma Inc.

1. Quick Overview

1.1. Quick analysis of Propanc (30 sec.)










1.2. What can you expect buying and holding a share of Propanc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$-0.01
Expected worth in 1 year
$-0.01
How sure are you?
42.5%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-251.6%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0003 - $0.0004
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Propanc (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-0.02 - $-0.02
Total Value Per Share
$-0.03 - $-0.02

2.2. Growth of Propanc (5 min.)




Is Propanc growing?

Current yearPrevious yearGrowGrow %
How rich?-$3.7m-$2.9m-$572.4k-16.3%

How much money is Propanc making?

Current yearPrevious yearGrowGrow %
Making money-$502.1k-$655.4k$153.2k30.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Propanc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Propanc?

Welcome investor! Propanc's management wants to use your money to grow the business. In return you get a share of Propanc.

First you should know what it really means to hold a share of Propanc. And how you can make/lose money.

Speculation

The Price per Share of Propanc is $0.0003. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Propanc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Propanc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.01. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Propanc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-173.7%0.00-243.3%0.00-378.7%0.00-379.2%0.00-588.3%
Usd Book Value Change Per Share0.00-38.5%0.00-80.2%0.00-11.3%0.0012.6%0.00-28.7%
Usd Dividend Per Share0.000.0%0.0017.3%0.00136.8%0.0033.6%0.0016.8%
Usd Total Gains Per Share0.00-38.5%0.00-62.9%0.00125.5%0.0046.2%0.00-11.9%
Usd Price Per Share0.00-0.01-0.61-95.39-246.66-
Price to Earnings Ratio-0.62--3.38--136.14--19,237.45--31,062.16-
Price-to-Total Gains Ratio-11.24-5.06--2,443.35-258,347.44--846,783.79-
Price to Book Ratio-0.24--2.19--146.67--16,419.33--38,838.37-
Price-to-Total Gains Ratio-11.24-5.06--2,443.35-258,347.44--846,783.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0003
Number of shares3333333
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (3333333 shares)-628.98462.41
Gains per Year (3333333 shares)-2,515.931,849.66
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1691-3207-252613445061840
21381-6413-5042268710123690
32072-9620-7558403115185540
42763-12827-10074537520247390
53454-16033-12590671825309240
64144-19240-151068062303611090
74835-22447-176229406354212940
85526-25653-2013810749404814790
96217-28860-2265412093455416640
106907-32067-2517013437506018490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.039.00.02.5%2.049.02.03.8%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%7.011.02.035.0%15.023.02.037.5%16.034.03.030.2%
Dividend per Share1.00.03.025.0%5.00.07.041.7%5.00.015.025.0%5.00.035.012.5%5.00.048.09.4%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%9.09.02.045.0%17.021.02.042.5%18.032.03.034.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Propanc Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0000.000+108%0.000-71%0.000-405%0.000-25%
Book Value Per Share---0.005-0.005-7%-0.004-22%-0.005-9%-0.005-1%
Current Ratio--0.0070.028-76%0.017-61%0.018-63%0.050-87%
Debt To Asset Ratio--53.22246.653+14%33.121+61%57.902-8%45.993+16%
Debt To Equity Ratio----0%-0%-0%-0%
Dividend Per Share---0.000-100%0.000-100%0.000-100%0.000-100%
Eps---0.001-0.001+40%-0.001+118%-0.001+118%-0.002+239%
Free Cash Flow Per Share--0.0000.000-10%0.000+6%0.000+22%-0.001+78%
Free Cash Flow To Equity Per Share--0.0000.000-615%0.000-525%0.000+31%0.000-360%
Gross Profit Margin--1.0411.008+3%1.000+4%1.002+4%1.014+3%
Intrinsic Value_10Y_max---0.016--------
Intrinsic Value_10Y_min---0.025--------
Intrinsic Value_1Y_max---0.002--------
Intrinsic Value_1Y_min---0.003--------
Intrinsic Value_3Y_max---0.005--------
Intrinsic Value_3Y_min---0.008--------
Intrinsic Value_5Y_max---0.008--------
Intrinsic Value_5Y_min---0.013--------
Market Cap206406.605-333%894428.6217035025.114-87%418833402.240-100%65630795078.239-100%169709418007.599-100%
Net Profit Margin----0%-0%-0%-9.0110%
Operating Margin----0%-0%-0%-5.6880%
Operating Ratio----0%-0%-0%5.726-100%
Pb Ratio-0.055+77%-0.237-2.191+826%-146.668+61869%-16419.328+6937246%-38838.370+16409537%
Pe Ratio-0.144+77%-0.624-3.384+443%-136.139+21731%-19237.447+3084830%-31062.161+4981050%
Price Per Share0.000-333%0.0010.010-87%0.609-100%95.391-100%246.663-100%
Price To Free Cash Flow Ratio-0.198+77%-0.860-6.817+693%-360.044+41759%-54060.632+6284997%-139541.994+16223072%
Price To Total Gains Ratio-2.595+77%-11.2455.061-322%-2443.349+21629%258347.444-100%-846783.786+7530392%
Quick Ratio--0.0060.026-75%0.013-52%0.015-57%0.031-80%
Return On Assets---4.955-6.174+25%-7.259+46%-11.364+129%-11.091+124%
Return On Equity----0%-0%-0%-0%
Total Gains Per Share--0.0000.000+63%0.000-131%0.000-183%0.000-69%
Usd Book Value---3779059.000-3507858.500-7%-2935386.250-22%-3438157.100-9%-3749167.600-1%
Usd Book Value Change Per Share--0.0000.000+108%0.000-71%0.000-405%0.000-25%
Usd Book Value Per Share---0.005-0.005-7%-0.004-22%-0.005-9%-0.005-1%
Usd Dividend Per Share---0.000-100%0.000-100%0.000-100%0.000-100%
Usd Eps---0.001-0.001+40%-0.001+118%-0.001+118%-0.002+239%
Usd Free Cash Flow---259966.000-234633.000-10%-276312.750+6%-316666.900+22%-463743.115+78%
Usd Free Cash Flow Per Share--0.0000.000-10%0.000+6%0.000+22%-0.001+78%
Usd Free Cash Flow To Equity Per Share--0.0000.000-615%0.000-525%0.000+31%0.000-360%
Usd Market Cap206406.605-333%894428.6217035025.114-87%418833402.240-100%65630795078.239-100%169709418007.599-100%
Usd Price Per Share0.000-333%0.0010.010-87%0.609-100%95.391-100%246.663-100%
Usd Profit---358578.000-502144.500+40%-655434.000+83%-626756.850+75%-1136360.400+217%
Usd Revenue----0%-0%-0%2064.500-100%
Usd Total Gains Per Share--0.0000.000+63%0.000-131%0.000-183%0.000-69%
 EOD+2 -6MRQTTM+10 -20YOY+10 -205Y+12 -1810Y+11 -21

3.3 Fundamental Score

Let's check the fundamental score of Propanc Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.144
Price to Book Ratio (EOD)Between0-1-0.055
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.006
Current Ratio (MRQ)Greater than10.007
Debt to Asset Ratio (MRQ)Less than153.222
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-4.955
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Propanc Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.922
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Propanc Biopharma Inc

Propanc Biopharma, Inc., a biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research collaboration with University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation; and a joint research and drug discovery program with Universities of Jaén and Granada for the POP1 program to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Fundamental data was last updated by Penke on 2024-11-15 11:35:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Propanc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Propanc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Propanc Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-901.1%+901.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--115.9%+115.9%
TTM--210.8%+210.8%
YOY--214.5%+214.5%
5Y--342.2%+342.2%
10Y-901.1%-464.5%-436.6%
4.3.1.2. Return on Assets

Shows how efficient Propanc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Propanc to the Biotechnology industry mean.
  • -495.5% Return on Assets means that Propanc generated $-4.96 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Propanc Biopharma Inc:

  • The MRQ is -495.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -617.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-495.5%TTM-617.4%+121.9%
TTM-617.4%YOY-725.9%+108.4%
TTM-617.4%5Y-1,136.4%+519.0%
5Y-1,136.4%10Y-1,109.1%-27.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-495.5%-11.1%-484.4%
TTM-617.4%-11.7%-605.7%
YOY-725.9%-11.3%-714.6%
5Y-1,136.4%-12.7%-1,123.7%
10Y-1,109.1%-14.3%-1,094.8%
4.3.1.3. Return on Equity

Shows how efficient Propanc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Propanc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Propanc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Propanc Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--15.8%+15.8%
YOY--13.9%+13.9%
5Y--18.5%+18.5%
10Y--19.5%+19.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Propanc Biopharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Propanc is operating .

  • Measures how much profit Propanc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Propanc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Propanc Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-568.8%+568.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--258.6%+258.6%
TTM--318.3%+318.3%
YOY--224.0%+224.0%
5Y--386.5%+386.5%
10Y-568.8%-497.6%-71.2%
4.3.2.2. Operating Ratio

Measures how efficient Propanc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Propanc Biopharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y5.726-5.726
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.594-2.594
TTM-3.360-3.360
YOY-3.299-3.299
5Y-4.788-4.788
10Y5.7266.528-0.802
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Propanc Biopharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Propanc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.01 means the company has $0.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Propanc Biopharma Inc:

  • The MRQ is 0.007. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.028. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.007TTM0.028-0.021
TTM0.028YOY0.017+0.011
TTM0.0285Y0.018+0.010
5Y0.01810Y0.050-0.032
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0073.658-3.651
TTM0.0283.874-3.846
YOY0.0174.672-4.655
5Y0.0185.960-5.942
10Y0.0506.277-6.227
4.4.3.2. Quick Ratio

Measures if Propanc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Propanc to the Biotechnology industry mean.
  • A Quick Ratio of 0.01 means the company can pay off $0.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Propanc Biopharma Inc:

  • The MRQ is 0.006. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.026. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.006TTM0.026-0.019
TTM0.026YOY0.013+0.012
TTM0.0265Y0.015+0.011
5Y0.01510Y0.031-0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0063.104-3.098
TTM0.0263.426-3.400
YOY0.0134.498-4.485
5Y0.0155.933-5.918
10Y0.0316.426-6.395
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Propanc Biopharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Propanc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Propanc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 53.22 means that Propanc assets are financed with 5,322.2% credit (debt) and the remaining percentage (100% - 5,322.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Propanc Biopharma Inc:

  • The MRQ is 53.222. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 46.653. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ53.222TTM46.653+6.569
TTM46.653YOY33.121+13.531
TTM46.6535Y57.902-11.250
5Y57.90210Y45.993+11.910
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ53.2220.354+52.868
TTM46.6530.345+46.308
YOY33.1210.311+32.810
5Y57.9020.366+57.536
10Y45.9930.382+45.611
4.5.4.2. Debt to Equity Ratio

Measures if Propanc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Propanc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Propanc Biopharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM-0.437-0.437
YOY-0.378-0.378
5Y-0.452-0.452
10Y-0.495-0.495
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Propanc generates.

  • Above 15 is considered overpriced but always compare Propanc to the Biotechnology industry mean.
  • A PE ratio of -0.62 means the investor is paying $-0.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Propanc Biopharma Inc:

  • The EOD is -0.144. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.624. Based on the earnings, the company is expensive. -2
  • The TTM is -3.384. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.144MRQ-0.624+0.480
MRQ-0.624TTM-3.384+2.761
TTM-3.384YOY-136.139+132.755
TTM-3.3845Y-19,237.447+19,234.062
5Y-19,237.44710Y-31,062.161+11,824.715
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.144-2.160+2.016
MRQ-0.624-2.428+1.804
TTM-3.384-3.145-0.239
YOY-136.139-3.304-132.835
5Y-19,237.447-6.080-19,231.367
10Y-31,062.161-6.625-31,055.536
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Propanc Biopharma Inc:

  • The EOD is -0.198. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.860. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.817. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.198MRQ-0.860+0.662
MRQ-0.860TTM-6.817+5.957
TTM-6.817YOY-360.044+353.227
TTM-6.8175Y-54,060.632+54,053.815
5Y-54,060.63210Y-139,541.994+85,481.361
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.198-2.980+2.782
MRQ-0.860-3.295+2.435
TTM-6.817-3.682-3.135
YOY-360.044-4.523-355.521
5Y-54,060.632-8.162-54,052.470
10Y-139,541.994-9.239-139,532.755
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Propanc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.24 means the investor is paying $-0.24 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Propanc Biopharma Inc:

  • The EOD is -0.055. Based on the equity, the company is expensive. -2
  • The MRQ is -0.237. Based on the equity, the company is expensive. -2
  • The TTM is -2.191. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.055MRQ-0.237+0.182
MRQ-0.237TTM-2.191+1.954
TTM-2.191YOY-146.668+144.477
TTM-2.1915Y-16,419.328+16,417.137
5Y-16,419.32810Y-38,838.370+22,419.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0551.869-1.924
MRQ-0.2372.027-2.264
TTM-2.1912.365-4.556
YOY-146.6682.419-149.087
5Y-16,419.3283.668-16,422.996
10Y-38,838.3704.362-38,842.732
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets72
Total Liabilities3,851
Total Stockholder Equity-3,779
 As reported
Total Liabilities 3,851
Total Stockholder Equity+ -3,779
Total Assets = 72

Assets

Total Assets72
Total Current Assets25
Long-term Assets47
Total Current Assets
Cash And Cash Equivalents 21
Net Receivables 3
Total Current Assets  (as reported)25
Total Current Assets  (calculated)24
+/- 1
Long-term Assets
Property Plant Equipment 18
Long-term Assets Other 29
Long-term Assets  (as reported)47
Long-term Assets  (calculated)47
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,793
Long-term Liabilities59
Total Stockholder Equity-3,779
Total Current Liabilities
Short-term Debt 890
Accounts payable 1,213
Other Current Liabilities 1,690
Total Current Liabilities  (as reported)3,793
Total Current Liabilities  (calculated)3,793
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)59
Long-term Liabilities  (calculated)0
+/- 59
Total Stockholder Equity
Common Stock479
Retained Earnings -66,698
Accumulated Other Comprehensive Income 1,270
Other Stockholders Equity 61,171
Total Stockholder Equity (as reported)-3,779
Total Stockholder Equity (calculated)-3,779
+/-0
Other
Cash and Short Term Investments 21
Common Stock Shares Outstanding 478,802
Current Deferred Revenue887
Liabilities and Stockholders Equity 72
Net Debt 927
Net Working Capital -3,767
Short Long Term Debt Total 948



6.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-31
> Total Assets 
0
0
10,814
0
4,873
2,159
46
27
12
4
2
2
12
0
114
114
53
310
627
305
1,508
1,623
379
181
136
45
95
163
129
111
71
83
713
260
102
102
65
64
99
99
41
28
13
62
110
169
82
94
108
144
60
180
242
37
72
72372421806014410894821691106213284199996465102102260713837111112916395451361813791,6231,508305627310531141140122241227462,1594,873010,81400
   > Total Current Assets 
0
0
10,780
0
4,841
2,127
42
23
8
0
0
1
12
0
0
114
53
309
622
300
1,503
1,618
363
167
123
31
82
150
117
99
61
73
388
249
91
91
21
32
69
69
23
19
7
56
85
145
15
38
54
97
19
146
211
13
25
2513211146199754381514585567192369693221919124938873619911715082311231673631,6181,503300622309531140012100823422,1274,841010,78000
       Cash And Cash Equivalents 
0
0
0
0
40
39
0
1
0
0
0
37
1
0
88
88
15
168
108
77
1,168
1,479
121
25
43
9
69
143
112
9
20
39
125
107
2
2
12
27
67
67
21
14
2
46
74
134
4
19
24
93
10
7
72
6
21
21672710932419413474462142167672712221071253920911214369943251211,4791,1687710816815888801370001039400000
       Net Receivables 
0
0
2
0
4
1
3
0
2
0
0
1
5
0
0
1
2
6
12
15
7
22
29
10
10
10
8
7
4
2
6
2
9
4
5
5
2
5
2
2
2
4
4
2
6
2
2
3
5
3
3
119
127
5
3
351271193353226244222525549262478101010292271512621005100203140200
       Other Current Assets 
0
0
10,778
0
4,797
2,086
0
22
5
0
0
0
7
0
25
25
36
134
503
207
328
117
212
132
69
12
5
7
4
88
35
32
255
137
0
83
6
5
0
0
0
4
0
8
6
8
9
16
25
3
6
160
151
8
6
681511606325169868040005683013725532358847512691322121173282075031343625250700052202,0864,797010,77800
   > Long-term Assets 
0
0
34
0
32
32
5
4
4
4
0
1
0
0
0
0
0
1
5
5
5
5
16
15
13
14
13
13
12
11
10
10
325
11
11
11
45
32
29
29
17
10
7
6
25
25
67
56
54
47
41
35
31
24
47
472431354147545667252567101729293245111111325101011121313141315165555100000104445323203400
       Property Plant Equipment 
0
0
7
0
5
5
5
4
4
4
1
1
0
0
0
0
0
1
3
4
4
4
13
12
11
11
11
10
10
9
8
8
9
9
8
8
43
31
27
27
15
7
4
4
3
3
65
54
52
45
39
33
29
23
18
1823293339455254653344715272731438899889101011111112134443100000114445550700
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002000000000000000000000000000000000
       Intangible Assets 
0
0
28
0
26
27
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000272602800
       Other Assets 
0
0
0
0
27
27
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
3
0
2
2
3
2
0
0
0
2
0
0
0
2
0
2
2
2
2
2
2
2
2
0
22
2
2
0
0
2
0
0
0
0
0000200222202222222202000200023220300200000000000027270000
> Total Liabilities 
0
0
307
0
354
482
584
637
656
752
794
794
1,062
1,165
1,522
1,522
1,930
2,161
3,681
3,487
4,864
5,144
2,944
1,985
3,976
4,760
5,537
6,900
7,278
6,884
6,823
5,641
4,617
3,673
4,403
4,403
5,737
4,911
3,740
3,740
3,649
3,032
3,081
2,369
3,040
3,117
3,105
2,862
3,023
3,085
3,178
3,170
3,806
3,737
3,851
3,8513,7373,8063,1703,1783,0853,0232,8623,1053,1173,0402,3693,0813,0323,6493,7403,7404,9115,7374,4034,4033,6734,6175,6416,8236,8847,2786,9005,5374,7603,9761,9852,9445,1444,8643,4873,6812,1611,9301,5221,5221,1651,062794794752656637584482354030700
   > Total Current Liabilities 
0
0
307
0
354
482
584
637
656
752
794
794
1,062
1,165
1,522
1,522
1,930
2,161
3,681
3,487
4,864
5,144
2,944
1,985
3,976
4,760
5,537
6,900
7,278
6,884
6,823
5,641
4,617
3,673
4,403
4,403
5,714
4,891
3,740
3,740
3,649
3,032
3,081
2,369
3,040
3,117
3,063
2,822
2,993
3,060
3,158
3,133
3,762
3,688
3,793
3,7933,6883,7623,1333,1583,0602,9932,8223,0633,1173,0402,3693,0813,0323,6493,7403,7404,8915,7144,4034,4033,6734,6175,6416,8236,8847,2786,9005,5374,7603,9761,9852,9445,1444,8643,4873,6812,1611,9301,5221,5221,1651,062794794752656637584482354030700
       Short-term Debt 
0
0
0
0
69
143
75
17
38
38
0
33
43
75
0
468
503
1,166
1,822
2,155
1,952
1,001
1,205
549
1,826
2,654
3,482
4,656
4,420
4,572
4,754
3,812
2,851
2,120
1,709
1,709
3,001
2,764
0
1,634
1,281
1,014
680
638
1,026
1,131
1,056
976
843
656
527
657
975
883
890
8908839756575276568439761,0561,1311,0266386801,0141,2811,63402,7643,0011,7091,7092,1202,8513,8124,7544,5724,4204,6563,4822,6541,8265491,2051,0011,9522,1551,8221,1665034680754333038381775143690000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,946
3,751
3,539
4,714
4,478
4,572
4,754
0
0
2,120
1,709
2,597
2,986
2,756
1,609
1,083
1,266
1,007
680
638
1,026
1,131
1,035
961
822
635
505
636
952
861
0
08619526365056358229611,0351,1311,0266386801,0071,2661,0831,6092,7562,9862,5971,7092,120004,7544,5724,4784,7143,5393,7512,946000000000000000000000000
       Accounts payable 
0
0
28
0
39
38
192
239
198
211
273
273
311
332
350
350
88
291
236
303
107
159
370
326
442
452
484
607
1,439
1,210
1,157
1,134
1,063
855
917
917
827
1,006
842
842
1,020
950
1,002
826
921
967
943
899
914
918
967
1,081
1,158
1,188
1,213
1,2131,1881,1581,0819679189148999439679218261,0029501,0208428421,0068279179178551,0631,1341,1571,2101,43960748445244232637015910730323629188350350332311273273211198239192383902800
       Other Current Liabilities 
0
0
279
0
246
301
317
381
419
504
357
489
164
111
703
158
1,005
146
1,050
437
2,593
3,740
1,050
833
1,120
1,098
881
1,161
1,002
555
372
157
66
11
698
698
925
318
208
177
23
53
54
58
222
1,019
1,064
947
1,235
1,486
423
1,394
1,630
1,617
1,690
1,6901,6171,6301,3944231,4861,2359471,0641,0192225854532317720831892569869811661573725551,0021,1618811,0981,1208331,0503,7402,5934371,0501461,005158703111164489357504419381317301246027900
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
23
20
0
0
0
0
0
0
1,947
2,098
42
39
31
25
19
37
43
49
59
5949433719253139422,0981,94700000020232200000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
314
0
0
0
0
0
0
0
0
0
0
0
20
20
0
0
0
0
0
0
0
0
0
00000000020200000000000031400000000000000000000000000000000
> Total Stockholder Equity
0
0
10,507
0
4,519
1,676
-538
-610
-643
-748
0
-792
-1,050
-1,165
0
-1,408
-1,877
-1,851
-3,054
-3,182
-3,356
-3,521
-2,565
-1,804
-3,841
-4,715
-5,442
-6,738
-7,149
-6,773
-6,752
-5,558
-3,904
-3,413
-4,301
-4,301
-5,672
-4,847
-3,641
-3,641
-3,608
-3,004
-3,068
-2,307
-2,930
-2,947
-3,024
-2,768
-2,915
-2,941
-3,117
-2,989
-3,564
-3,700
-3,779
-3,779-3,700-3,564-2,989-3,117-2,941-2,915-2,768-3,024-2,947-2,930-2,307-3,068-3,004-3,608-3,641-3,641-4,847-5,672-4,301-4,301-3,413-3,904-5,558-6,752-6,773-7,149-6,738-5,442-4,715-3,841-1,804-2,565-3,521-3,356-3,182-3,054-1,851-1,877-1,4080-1,165-1,050-7920-748-643-610-5381,6764,519010,50700
   Common Stock
0
0
72
0
72
72
73
73
73
71
71
71
73
73
73
73
131
333
347
357
433
602
729
794
867
4
5
7
18
31
46
176
273
385
1
1
2
18
258
258
2
5
14
46
53
86
240
677
1,246
2,621
8
15
36
110
479
479110361582,6211,24667724086534614522582581821138527317646311875486779472960243335734733313173737373717171737373727207200
   Retained Earnings Total Equity00000-63,8790000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-120
0
-455
-307
-359
-369
-369
-372
0
-245
-229
-277
0
-303
-85
47
101
359
213
-25
131
-94
388
-86
-142
-331
-312
-113
358
634
992
877
0
1,067
1,001
3,283
0
1,268
1,024
1,054
1,085
1,149
1,142
1,087
1,235
1,361
1,253
1,294
1,295
1,369
1,234
1,339
1,270
1,2701,3391,2341,3691,2951,2941,2531,3611,2351,0871,1421,1491,0851,0541,0241,26803,2831,0011,0670877992634358-113-312-331-142-86388-94131-2521335910147-85-3030-277-229-2450-372-369-369-359-307-4550-12000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,069
0
0
0
0
0
0000057,0690000000000000000000000000000000000000000000000000
   Treasury Stock00000-4600000000000000000-46-46-47-47-47-4600000000000000000000000000
   Other Stockholders Equity 
0
0
14,292
0
14,530
14,633
15,029
15,459
15,445
15,680
0
15,874
16,375
16,375
0
16,375
16,753
16,903
17,459
17,901
21,360
23,416
26,946
28,969
30,138
31,972
32,934
33,749
35,509
37,165
38,121
41,035
43,683
44,759
1,067
45,667
47,720
48,833
1,268
50,610
51,972
52,961
54,028
55,298
55,568
56,273
57,055
57,754
57,650
57,023
60,265
60,805
60,963
61,191
61,171
61,17161,19160,96360,80560,26557,02357,65057,75457,05556,27355,56855,29854,02852,96151,97250,6101,26848,83347,72045,6671,06744,75943,68341,03538,12137,16535,50933,74932,93431,97230,13828,96926,94623,41621,36017,90117,45916,90316,75316,375016,37516,37515,874015,68015,44515,45915,02914,63314,530014,29200



6.3. Balance Sheets

All numbers in thousands.




6.4. Cash Flows

All numbers in thousands.




6.5. Income Statements

All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-06-30. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-34
Gross Profit-34-34
 
Operating Income (+$)
Gross Profit-34
Operating Expense-1,536
Operating Income-1,536-1,570
 
Operating Expense (+$)
Research Development248
Selling General Administrative1,254
Selling And Marketing Expenses34
Operating Expense1,5361,536
 
Net Interest Income (+$)
Interest Income0
Interest Expense--666
Other Finance Cost-666
Net Interest Income0
 
Pretax Income (+$)
Operating Income-1,536
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,950-1,122
EBIT - interestExpense = -871
-1,691
-2,486
Interest Expense-666
Earnings Before Interest and Taxes (EBIT)-1,536-2,616
Earnings Before Interest and Taxes (EBITDA)-1,536
 
After tax Income (+$)
Income Before Tax-1,950
Tax Provision-0
Net Income From Continuing Ops0-1,950
Net Income-1,821
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,536
Total Other Income/Expenses Net-4140
 

Technical Analysis of Propanc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Propanc. The general trend of Propanc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Propanc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Propanc Biopharma Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0004 < 0.0004 < 0.0004.

The bearish price targets are: 0.0003 > 0.0003 > 0.0003.

Tweet this
Propanc Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Propanc Biopharma Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Propanc Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Propanc Biopharma Inc. The current macd is -0.000019.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Propanc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Propanc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Propanc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Propanc Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartPropanc Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Propanc Biopharma Inc. The current adx is 28.06.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Propanc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Propanc Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Propanc Biopharma Inc. The current sar is 0.0002.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Propanc Biopharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Propanc Biopharma Inc. The current rsi is 41.92. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Propanc Biopharma Inc Daily Relative Strength Index (RSI) ChartPropanc Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Propanc Biopharma Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -3/(-6 +6).

  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Propanc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Propanc Biopharma Inc Daily Stochastic Oscillator ChartPropanc Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Propanc Biopharma Inc. The current cci is -82.78867102.

Propanc Biopharma Inc Daily Commodity Channel Index (CCI) ChartPropanc Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Propanc Biopharma Inc. The current cmo is -27.50132811.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Propanc Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartPropanc Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Propanc Biopharma Inc. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Propanc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Propanc Biopharma Inc Daily Williams %R ChartPropanc Biopharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Propanc Biopharma Inc.

Propanc Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Propanc Biopharma Inc. The current atr is 0.000090.

Propanc Biopharma Inc Daily Average True Range (ATR) ChartPropanc Biopharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Propanc Biopharma Inc. The current obv is -248,474,505.

Propanc Biopharma Inc Daily On-Balance Volume (OBV) ChartPropanc Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Propanc Biopharma Inc. The current mfi is 26.94.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Propanc Biopharma Inc Daily Money Flow Index (MFI) ChartPropanc Biopharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Propanc Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-24ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.

6.3. Candlestick Patterns

Propanc Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Propanc Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.922
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Propanc with someone you think should read this too:
  • Are you bullish or bearish on Propanc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Propanc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Propanc Biopharma Inc

I send you an email if I find something interesting about Propanc Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Propanc Biopharma Inc.

Receive notifications about Propanc Biopharma Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.